Trials / Active Not Recruiting
Active Not RecruitingNCT04423731
Neoadjuvant Chemotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer (NORPACT-2)
Neoadjuvant Chemotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer - A Norwegian Population Based Observational Study (NORPACT-2)
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 251 (actual)
- Sponsor
- Oslo University Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
This is a Norwegian prospective observational study that evaluates the resectability rate in patients with borderline resectable and locally advanced pancreatic cancer who received neoadjuvant chemotherapy in a population based cohort. Eligible patients are treated with neoadjuvant chemotherapy possibly followed by surgical exploration and resection. All Norwegian centres performing pancreatic surgery have agreed to collaborate in this trial. The assignment of the medical intervention is not at the discretion of the investigator, but follow the national Norwegian guidelines regarding diagnostic work up, oncological and surgical treatment and follow up.
Conditions
- Locally Advanced Pancreatic Adenocarcinoma
- Chemotherapy Effect
- Borderline Resectable Pancreatic Adenocarcinoma
- Pancreatectomy
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Folfirinox | Neoadjuvant chemotherapy is given according to different regimens, preferably FOLFIRINOX according to the recommendations in the national Norwegian guidelines. The choice of chemotherapy regimen is decided by the treating oncologist. |
Timeline
- Start date
- 2018-01-01
- Primary completion
- 2022-10-31
- Completion
- 2025-12-31
- First posted
- 2020-06-09
- Last updated
- 2024-11-20
Locations
1 site across 1 country: Norway
Source: ClinicalTrials.gov record NCT04423731. Inclusion in this directory is not an endorsement.